Figure 1. Hematoxylin and eosin-stained sections showing tumor cells with positive reaction to CD30 marker.
Figure 2. (A) Tumor at baseline just before the start of brentuximab treatment. (B) Shows response to brentuximab with regression of tumor burden. (C) Shows progression under brentuximab treatment.
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
To request a reprint or corporate permissions for this article, please click on the relevant link below:
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
Obtain permissions instantly via Rightslink by clicking on the button below:
If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.
